M. Martín Jiménez

994 total citations
56 papers, 323 citations indexed

About

M. Martín Jiménez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, M. Martín Jiménez has authored 56 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in M. Martín Jiménez's work include Advanced Breast Cancer Therapies (27 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (17 papers). M. Martín Jiménez is often cited by papers focused on Advanced Breast Cancer Therapies (27 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Treatment and Pharmacology (17 papers). M. Martín Jiménez collaborates with scholars based in Spain, United States and Italy. M. Martín Jiménez's co-authors include Andrés J. Muñoz Martín, Pilar Alfonso, Luis Sierrasesúmaga, Sara Ramírez, M Navarro, Carme Font, Christian Schem, Amit Bardia, Sara López‐Tarruella and Philip R. Debruyne and has published in prestigious journals such as Cancer Research, Journal of Hepatology and Annals of Oncology.

In The Last Decade

M. Martín Jiménez

50 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Martín Jiménez Spain	10	200	133	79	68	36	56	323
Anders Christian Larsen Denmark	12	176 0.9×	100 0.8×	114 1.4×	76 1.1×	13 0.4×	28	405
Diana Kassab‐Chahmi France	8	48 0.2×	109 0.8×	57 0.7×	65 1.0×	34 0.9×	13	275
J-L. Canon Belgium	9	264 1.3×	119 0.9×	30 0.4×	18 0.3×	14 0.4×	29	406
Anne O. Rodriguez United States	7	130 0.7×	30 0.2×	48 0.6×	130 1.9×	39 1.1×	8	335
Jwa Hoon Kim South Korea	11	182 0.9×	112 0.8×	44 0.6×	30 0.4×	5 0.1×	30	348
C Brambilla France	8	73 0.4×	153 1.2×	36 0.5×	35 0.5×	11 0.3×	30	327
Jodi V. Mones United States	8	90 0.5×	41 0.3×	10 0.1×	84 1.2×	103 2.9×	21	283
Tamara A. Sussman United States	9	146 0.7×	29 0.2×	13 0.2×	80 1.2×	12 0.3×	31	250
Linda C. DeMarco United States	6	124 0.6×	136 1.0×	45 0.6×	10 0.1×	16 0.4×	11	284
G.F. Samelis Greece	10	247 1.2×	159 1.2×	24 0.3×	15 0.2×	19 0.5×	23	372

Countries citing papers authored by M. Martín Jiménez

Since Specialization

Citations

This map shows the geographic impact of M. Martín Jiménez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Martín Jiménez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Martín Jiménez more than expected).

Fields of papers citing papers by M. Martín Jiménez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Martín Jiménez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Martín Jiménez. The network helps show where M. Martín Jiménez may publish in the future.

Co-authorship network of co-authors of M. Martín Jiménez

This figure shows the co-authorship network connecting the top 25 collaborators of M. Martín Jiménez. A scholar is included among the top collaborators of M. Martín Jiménez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Martín Jiménez. M. Martín Jiménez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hecht, J. Randolph, Elena Garralda, Hong Jae Chon, et al.. (2025). Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. The Oncologist. 30(3). 1 indexed citations

López‐Tarruella, Sara, et al.. (2025). Randomized pilot study of an individualized multimodal exercise, nutrition, and behavior intervention in breast cancer patients treated with ovarian function suppression: protocol proposal for The OvS Breast ENBI Project. Frontiers in Oncology. 15. 1622622–1622622.

Barrios, Carlos H., Nadia Harbeck, Gabriel N. Hortobágyi, et al.. (2024). 113MO NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). ESMO Open. 9. 103101–103101. 2 indexed citations

Waks, Adrienne G., Guillermo Villacampa, Nadine Tung, et al.. (2023). 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies. ESMO Open. 8(1). 101465–101465. 1 indexed citations

O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations

Morán, L. Ortega, et al.. (2023). 2146P Cancer-associated thrombosis clinic: Experience of the Medical Oncology Department of a hospital in Spain. Annals of Oncology. 34. S1117–S1118. 1 indexed citations

Villacampa, Guillermo, Tomás Pascual, María Vidal, et al.. (2023). 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer. ESMO Open. 8(1). 101231–101231. 3 indexed citations

Neven, Patrick, Neil Stahl, María Vidal, et al.. (2023). 273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2. Annals of Oncology. 34. S292–S293. 4 indexed citations

Harbeck, Nadia, Priya Rastogi, J. O’Shaughnessy, et al.. (2023). LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Annals of Oncology. 34. S1256–S1256. 11 indexed citations

10.

Hamilton, E.P., Charles L. Shapiro, Valentina Boni, et al.. (2022). 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Annals of Oncology. 33. S196–S196. 31 indexed citations

11.

Jiménez, M. Martín, Elgene Lim, Amit Bardia, et al.. (2022). 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Annals of Oncology. 33. S633–S634. 43 indexed citations

12.

Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458. 3 indexed citations

13.

Curigliano, Giuseppe, M. Martín Jiménez, Toshio Shimizu, et al.. (2021). Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors. Cancer Research. 81(13_Supplement). CT103–CT103. 9 indexed citations

14.

Schettini, Francesco, Núria Chic, Fara Brasó‐Maristany, et al.. (2020). 23P Clinical, pathological and gene expression features of HER2-low breast cancer. Annals of Oncology. 31. S24–S24. 1 indexed citations

15.

Delaloge, Suzette, David Cella, Marc Buyse, et al.. (2017). Effects of neratinib (N) on health-related quality of life (HRQoL) in early-stage HER2+ breast cancer (BC): longitudinal analyses from the phase III ExteNET trial. Annals of Oncology. 28. v53–v53. 2 indexed citations

16.

Calvo, Aitana, Sara López‐Tarruella, Rosa Álvarez, et al.. (2017). Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. Annals of Oncology. 28. v135–v135.

17.

Jiménez, M. Martín, Aitana Calvo, Rosario García‐Campelo, et al.. (2016). New clinical trials regulation in Spain: analysis of royal decree 1090/2015. Clinical & Translational Oncology. 19(3). 291–300. 4 indexed citations

18.

Martín, Andrés J. Muñoz, et al.. (2016). Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncology Letters. 12(1). 727–730. 7 indexed citations

19.

Martín, Andrés J. Muñoz, et al.. (2014). Clinical guide SEOM on venous thromboembolism in cancer patients. Clinical & Translational Oncology. 16(12). 1079–1090. 19 indexed citations

20.

Jiménez, M. Martín, et al.. (1998). Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Medical and Pediatric Oncology. 30(2). 110–116. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact